长春高新(000661.SZ)：下属公司签署GenSci098注射液项目独家许可协议

Core Insights - Changchun High-tech (000661.SZ) has signed an exclusive licensing agreement for the GenSci098 injection project with Yarrow Bioscience, Inc. [1] - The agreement includes an upfront payment of $120 million, consisting of a non-refundable, non-offsettable payment of $70 million and a subsequent milestone payment of $50 million [1] - The company is eligible for up to $1.365 billion in milestone payments related to specific R&D, regulatory, and commercialization activities, along with over 10% sales commission on net sales after product launch [1] Financial Details - The initial payment structure includes a total of $120 million, with $70 million as an upfront payment and $50 million as a milestone payment [1] - Potential milestone payments could reach up to $1.365 billion, indicating significant future revenue opportunities [1] Product Information - GenSci098 is a humanized monoclonal antibody that acts as an antagonist to the thyroid-stimulating hormone receptor (TSHR), developed by Jinsai Pharmaceutical [1] - The product aims to treat hyperthyroidism by blocking TSHR interactions, thereby inhibiting the synthesis and release of thyroid hormones and reducing thyroid cell proliferation [1] - Additionally, GenSci098 has the potential to improve symptoms associated with exophthalmos [1]